

***Information for Pharmacists***

**Claims Submission Procedure –  
 Carbamazepine CR 200mg and 400mg Tablets**

***Effective July 2, 2024***

Please include this Procedure in your Drug Programs Information Network (DPIN) Manual under Section 4: Claims Submission.

**\*\*Pharmacies do NOT receive drug interaction information when submitting claims using PINs. Please review all claims carefully prior to submitting\*\***

- There is variable supply of the following products:

<b>Brand</b>	<b>DIN</b>	<b>Drug/Format</b>
Sandoz	02261839	Carbamazepine CR 200 mg Tablets
	02261847	Carbamazepine CR 400 mg Tablets
Tegretol	00773611	Carbamazepine CR 200mg Tablets
	00755583	Carbamazepine CR 400mg Tablets

- Due to this shortage, Manitoba is outlining the following product selection tree. This selection tree is to encourage pharmacy providers to use existing commercial supply while outlining an alternative option if supply is unavailable:
  - Commercially available product should be dispensed if the pharmacy has inventory on hand or can obtain product through normal distribution channels;
  - The pharmacy vendor may obtain commercially available product from another provider (e.g., another member within the same chain);
  - If Canadian labeled product cannot be obtained, then the US-labeled Carbamazepine CR 200mg and 400mg Tablets should be dispensed.
- The following PIN should be used when submitting claims for:
  - US-labeled Carbamazepine CR 200mg Tablets: 00912055
  - US-labeled Carbamazepine CR 400mg Tablets: 00912056
- Manitoba will inform pharmacy providers once the shortage has been resolved and the PIN is no longer required and has been withdrawn for coverage.

If your questions are not answered by reviewing the Claims Submission Procedures and  
FAQs posted at:

<https://www.gov.mb.ca/health/pharmacare/healthprofessionals.html>

Please send an e-mail to [NIBDrugShortages@gov.mb.ca](mailto:NIBDrugShortages@gov.mb.ca).